Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert(Institut Gustave Roussy), Antoni Ribas(University of California, Los Angeles), Jacob Schachter(Sheba Medical Center), Ana Arance(Hospital Clínic de Barcelona), Jean‐Jacques Grob(Hôpital de la Timone), Laurent Mortier(Centre Hospitalier Universitaire de Lille), Adil Daud(University of California, San Francisco), Matteo S. Carlino(Melanoma Institute Australia), Catriona M. McNeil(Royal Prince Alfred Hospital), Michal Lotem(Hadassah Medical Center), James Larkin(Royal Marsden Hospital), Paul Lorigan(University of Manchester), Bart Neyns(Universitair Ziekenhuis Brussel), Christian U. Blank(Dutch Cancer Society), Teresa M. Petrella(Health Sciences Centre), Omid Hamid(Angeles Clinic and Research Institute), Shu-Chih Su(Merck & Co., Inc., Rahway, NJ, USA (United States)), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Georgina V. Long(Royal North Shore Hospital)
Cited by 1,147
Abstract
Related Papers
No related papers found
Powered by citation graph analysis